OnKure Therapeutics develops small molecule drugs that target mutated forms of the PI3K alpha protein in cancer and other diseases. OKUR reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 14 | Oppenheimer | Reiterated | Buy | |
| Jul 20 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How OKUR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in OKUR in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OKUR is in one of them and how their past OKUR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered OKUR in an article yet. Here's the latest on the wider market.
About OnKure Therapeutics
OnKure Therapeutics is a biopharmaceutical company based in Boulder, Colorado. It develops small molecule drugs that target specific mutated forms of the PI3K alpha protein, a driver of cancer and other diseases, while sparing the normal form of the protein. Its lead candidate, OKI-219, is in Phase 1 clinical trials for patients with advanced breast cancer, and the company is also researching treatments for vascular malformations.
- Headquarters
- Boulder, CO